景峰医药
(000908)
| 流通市值：13.17亿 | | | 总市值：14.69亿 |
| 流通股本：7.89亿 | | | 总股本：8.80亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 553,833,803.69 | 380,521,926.69 | 176,056,130.03 | 840,657,161.99 |
| 营业收入 | 553,833,803.69 | 380,521,926.69 | 176,056,130.03 | 840,657,161.99 |
| 二、营业总成本 | 567,678,926.71 | 379,789,887.39 | 168,775,870.62 | 891,126,948.13 |
| 营业成本 | 135,355,103.15 | 84,630,054.57 | 39,763,582.42 | 199,332,595.27 |
| 税金及附加 | 8,790,023.04 | 5,178,459.68 | 2,042,021.92 | 12,326,939.16 |
| 销售费用 | 274,232,926.37 | 189,340,857.27 | 84,437,696.09 | 421,879,928.28 |
| 管理费用 | 107,743,645.16 | 71,516,596.32 | 27,890,733.42 | 170,646,365.24 |
| 研发费用 | 14,067,503.36 | 10,176,809.88 | 5,099,494.09 | 35,643,717.53 |
| 财务费用 | 27,489,725.63 | 18,947,109.67 | 9,542,342.68 | 51,297,402.65 |
| 其中:利息费用 | 28,562,581.08 | 18,833,137.2 | 8,223,602.21 | 52,404,385.99 |
| 其中:利息收入 | 1,094,333.91 | 556,553.82 | 224,760.67 | 1,121,503.61 |
| 加:公允价值变动收益 | - | - | - | 17,910,573.82 |
| 加:投资收益 | -736,553.51 | -732,366.26 | -22,989.16 | -4,089,862.51 |
| 资产处置收益 | -375,350.04 | -592,333.38 | -415,969.65 | 9,801,607.12 |
| 资产减值损失(新) | 52,092.39 | 1,568,040.96 | 1,842.95 | -45,278,454.86 |
| 信用减值损失(新) | 1,417,815.15 | 3,859,276.95 | 3,508,864.58 | -12,642,051.92 |
| 其他收益 | 11,292,874.1 | 9,755,175.59 | 573,517.74 | 16,450,946.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -2,194,244.93 | 14,589,833.16 | 10,925,525.87 | -68,317,027.61 |
| 加:营业外收入 | 348,974.52 | 157,280.73 | 70,463.69 | 808,962.78 |
| 减:营业外支出 | 5,135,014.21 | 4,830,105.87 | 319,466.09 | 18,124,182.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -6,980,284.62 | 9,917,008.02 | 10,676,523.47 | -85,632,247.24 |
| 减:所得税费用 | 7,207,415.28 | 4,322,224.92 | 1,933,272.52 | 10,332,076.08 |
| 六、净利润 | -14,187,699.9 | 5,594,783.1 | 8,743,250.95 | -95,964,323.32 |
| 持续经营净利润 | -14,187,699.9 | 5,594,783.1 | 8,743,250.95 | -95,964,323.32 |
| 归属于母公司股东的净利润 | -35,465,852.15 | -12,845,641.09 | 1,278,629.96 | -123,273,103.22 |
| 少数股东损益 | 21,278,152.25 | 18,440,424.19 | 7,464,620.99 | 27,308,779.9 |
| (一)基本每股收益 | -0.04 | -0.01 | 0 | -0.14 |
| (二)稀释每股收益 | -0.04 | -0.01 | 0 | -0.14 |
| 八、其他综合收益 | 370,752.68 | 758,879.47 | -601,135.13 | -1,124,674.96 |
| 归属于母公司股东的其他综合收益 | 189,083.87 | 387,028.53 | -306,578.92 | -629,797.16 |
| 九、综合收益总额 | -13,816,947.22 | 6,353,662.57 | 8,142,115.82 | -97,088,998.28 |
| 归属于母公司股东的综合收益总额 | -35,276,768.28 | -12,458,612.56 | 972,051.04 | -123,902,900.38 |
| 归属于少数股东的综合收益总额 | 21,459,821.06 | 18,812,275.13 | 7,170,064.78 | 26,813,902.1 |
| 公告日期 | 2023-10-31 | 2023-08-28 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 保留意见 |